Sandoz Group AG (VIE:SDZ)
Austria · Delayed Price · Currency is EUR | Market Cap | 30.83B +83.2% |
| Revenue (ttm) | 9.50B +7.4% |
| Net Income | 778.45M |
| EPS | 1.78 |
| Shares Out | n/a |
| PE Ratio | 39.60 |
| Forward PE | 19.98 |
| Dividend | 0.86 (1.21%) |
| Ex-Dividend Date | Apr 13, 2026 |
| Volume | n/a |
| Average Volume | 15 |
| Open | 70.88 |
| Previous Close | 71.42 |
| Day's Range | 70.88 - 71.70 |
| 52-Week Range | 52.52 - 78.84 |
| Beta | n/a |
| RSI | 49.80 |
| Earnings Date | Aug 5, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
News
Sandoz confirms the EC granted marketing authorization for Bysumlog, Dazparda
Sandoz (SDZNY) confirms that the European Commission, EC, has granted marketing authorization for Bysumlog and Dazparda. The two biosimilar insulins, for injection in prefilled pens, are developed by ...
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Sandoz upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Sandoz (SDZNY) to Overweight from Equal Weight with an unchanged price target of CHF 75. The firm finds the stock’s valuation “compelling” given Sandoz’s accelerating sales growth th...
Sandoz price target lowered to CHF 65 from CHF 70 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sandoz (SDZNY) to CHF 65 from CHF 70 and keeps a Hold rating on the shares.
Sandoz Group AG Earnings Call Transcript: Q1 2026
Q1 2026 saw robust biosimilar-driven growth, with net sales up 11% headline and 3% at constant currency, and biosimilars now 31% of sales. Generics faced headwinds but are expected to stabilize, while full-year guidance for mid to high single-digit growth and margin expansion is confirmed.
Sandoz Group AG Slides: Q1 2026
Sandoz Group AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Sandoz Group AG Earnings release: Q1 2026
Sandoz Group AG released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Sandoz Q1 Net Sales Up 3% At CC; Confirms 2026 Guidance
(RTTNews) - Sandoz (SDZ.SW) reported first quarter net sales of $2.76 billion compared to $2.48 billion, prior year. Sandoz said its performance was in line with company expectations. The company conf...
Sandoz price target raised to CHF 75 from CHF 66 at JPMorgan
JPMorgan analyst Sophia Graeff Buhl Nielsen raised the firm’s price target on Sandoz (SDZNY) to CHF 75 from CHF 66 and keeps an Overweight rating on the shares. Published first…
Sandoz initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Sandoz (SDZNY) with a Buy rating and CHF 74 price target The firm views Sandoz as a global leader in the generics and biosimilar industry.
Sandoz downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Natalia Webster downgraded Sandoz (SDZNY) to Sector Perform from Outperform with a price target of CHF 65, up from CHF 53. The firm cites valuation for the…
Sandoz announces partnership agreement with Samsung Bioepis
Sandoz (SDZNY) announced a major license, development and commercialization partnership agreement with Samsung Bioepis. The agreement paves the way for the two companies to partner on up to five biosi...
Sandoz price target raised to CHF 62 from CHF 55 at Berenberg
Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 62 from CHF 55 and keeps a Hold rating on the shares.
Sandoz downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Sandoz (SDZNY) to Hold from Buy with a CHF 70 price target
Sandoz downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Sandoz (SDZNY) to Equal Weight from Overweight with a price target of CHF 75, up from CHF 70. The firm cites valuation for the downgrade with the shares…
Sandoz Shares Jump on Improved Guidance
Stock rose 6.4% after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.
Sandoz Group AG Earnings Call Transcript: Q4 2025
Net sales grew 5% to $11.1B in 2025, with biosimilars now 30% of sales and core EBITDA margin up to 21.7%. Strong launches, strategic acquisitions, and robust pipeline support mid to high single-digit sales growth in 2026, despite ongoing generics pricing pressures.
Sandoz Group AG Earnings release: Q4 2025
Sandoz Group AG released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Sandoz Group AG Annual report: Q4 2025
Sandoz Group AG has published its Q4 2025 annual report on February 25, 2026.
Sandoz Group AG Slides: Q4 2025
Sandoz Group AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Sandoz confirms E.C. granted marketing authorization for Ranluspec
Sandoz (SDZNY) confirmed that the European Commission, E.C., has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on t...
Sandoz receives U.S. FDA approval to expand Enzeevu label
Sandoz (SDZNY) announced that the US Food and Drug Administration, FDA, has approved an expanded label for Enzeevu, to include multiple retinal indications. Enzeevu was originally approved by the FDA…
Sandoz upgraded to Buy from Hold at Jefferies
Jefferies analyst James Vane-Tempest upgraded Sandoz (SDZNY) to Buy from Hold with a price target of CHF 75, up from CHF 51.40. The firm believes the shares at current levels…
Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Sandoz (SDZNY) to CHF 63 from CHF 60 and keeps a Buy rating on the shares.
Sandoz price target raised to CHF 55 from CHF 49 at Berenberg
Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 55 from CHF 49 and keeps a Hold rating on the shares.